Objective: Epithelial cells participate in wound healing by covering wounds, but also as important mediators of wound healing processes. Topical application of the phospholipid growth factor lysophosphatidic acid (LPA) accelerates dermal wound healing and we hypothesized that LPA can play a role in human oral wound healing through its effects on human oral keratinocytes (HOK).
Introduction
Lysophosphatidic acid (LPA) is a growth factor-like lipid, and its biological effects on cells are mediated via G protein-coupled receptors, termed LPA1-6 (Yanagida, Kurikawa, Shimizu & Ishii, 2013) . LPA is a natural constituent of mammalian tissue fluids such as plasma, broncho-alveolar lavage fluid (Zhao & Natarajan, 2009) , saliva (Sugiura et al., 2002) and gingival crevicular fluid (GCF) Bathena et al., 2011) . LPA is produced by a number of cell types, including erythrocytes, leukocytes, activated platelets and human gingival fibroblasts (Blaho & Hla, 2011; Cerutis et al., 2015; Eichholtz, Jalink, Fahrenfort & Moolenaar, 1993) .
Wound healing is a dynamic process that involves four major processes that overlap in time (Martin, 1999; Eming et al., 2007) : hemostasis, inflammation, tissue formation, and remodeling and maturation. Several observations indicate that LPA plays a role in wound healing in skin and intestine. In vitro, LPA increases migration of human skin keratinocytes and rat intestinal epithelial cells (Sauer et al., 2004; Sturm, A et al. 1999) . In vivo, it accelerates repair of injured epithelia in rats with colitis (Sturm, A et al. 1999) , wound closing of rat skin (Balazs et al., 2002) and re-epithelialization during the early stages of wound healing in excisional ear wounds in mice (Demoyer et al., 2000) . In vitro studies have also shown that LPA increases rodent epidermal cell proliferation in vitro and after topical application of LPA on intact skin in vivo (Piazza GA, 1995) . Wound healing in the oral cavity is mostly uncomplicated and without much scarring (Wong et al., 2009 ), but it can be compromised in certain patients, e.g. those receiving radio-or chemotherapy (RaberDurlacher et al., 2013) or medication against osteoporosis (Marx, 2003) .
Little is known about the functions of LPA in the oral cavity. LPA, used at physiological concentrations in saliva, has been shown to increase proliferation of squamous carcinoma cells from the mouth, pharynx and esophagus (Sugiura et al., 2002) . In patients with chronic periodontitis, the concentration of LPA has been shown to be 5-10 times higher in saliva and gingival crevicular fluid as compared with healthy subjects (Bathena et al., 2011) . The gene expression profile of LPA-stimulated oral fibroblasts is characterized by up-regulation of inflammatory and wound healing genes as compared with unstimulated cells (Cerutis et al., 2015) .
Transcriptional profiling is a valuable tool to indicate unknown activities and profiling of LPA-stimulated murine embryonal fibroblasts unveiled activities of LPA in tissue remodeling, angiogenesis, inflammation and tumor progression (Stortelers, Kerkhoven & Moolenaar, 2008) . The transcriptional response to LPA in oral epithelial cells is unexplored.
As LPA modulates wound healing in the skin and the intestine, we presently aim to find support for the hypothesis that LPA can contribute to wound healing in the oral cavity through its effects on oral epithelial cells. To this end, we wanted to determine the LPA receptor expression in human oral keratinocytes (HOK), test if the receptors are functionally active, and examine the gene expression profile of HOK exposed to LPA. If indication can be found that LPA can improve oral wound healing, this physiological mediator might be considered for trials aimed at improving healing in acute or chronic oral wounds.
Material and methods

1. Biopsies and cell cultures
Biopsies were obtained from healthy volunteers during third molar extractions. The study was approved by Regional Ethical Committee of Health (REK South-East), and was carried out according to the Declaration of Helsinki's principal for biomedical research.
Written, informed consent was obtained from all donors. Primary human oral keratinocytes (HOK) were prepared from the biopsies. After transport in Dulbecco's Modified Eagle's Medium (DMEM) (Lonza BioWhittaker, Portsmouth, NH, USA) with 2 % penicillinstreptomycin-fungizone (PSF) (Lonza BioWhittaker), the biopsies were transferred to DMEM with 1.25 mg/ml dispase (GIBCO, Paisley, UK) and incubated over night at 4 °C. The epithelial sheets were peeled off, cut into small pieces and incubated in 10 X trypsin EDTA (SigmaAldrich, St Louis, MO, USA) for 7 min at 37 °C. A Pasteur pipette was used to loosen the cells.
Trypsinization was stopped by adding fetal calf serum (FCS). The cells were then cultured in keratinocyte serum-free medium (KSFM, GIBCO), supplemented with 25 µg/ml bovine pituitary extract (BPE; GIBCO), 1 µg/ml epidermal growth factor (GIBCO) and 1 % PSF in a humidified atmosphere of 5 % CO2 in air at 37 °C. In the experiments, 2 nd -6 th passaged cells were used. For all experiments, the cells were seeded at a desired density, incubated overnight and then grown in KSFM without addition of BPE and EGF 24 h before stimulation.
Lysophosphatidic acid (LPA)
LPA 18:1 was purchased from Avanti Polar Lipids (Alabaster, Alabama, USA) and dissolved in fatty acid-free bovine serum albumin (Sigma-Aldrich) in PBS to 2mM and stored at -20 °C until use. Fatty acid-free BSA was used as vehicle control in all experiments.
RNA isolation, reverse transcription and real-time qPCR
RNA was extracted from cell cultures by the use of RNeasy mini kit (74106; Qiagen, Hilden, Germany). The quantity and purity of the RNA was assessed with a NanoDrop spectrophotometer (ThermoFisher Scientific, Frederick, MD, USA). Total RNA (400 ng) was transcribed into cDNA by using a mixture of reverse transcriptase enzyme and random nonamers (Eurogentec, Seraing, Belgium). Each cDNA synthesis was performed in a total volume of 20 µl for 10 min at 25 °C, then 30 min at 48 °C and terminated by incubation for 5 min at 95 °C. Detection of mRNA was performed by using a Fast EvaGreen qPCR Master Mix Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a reference gene.
Illumina® bead array
Genome-wide transcriptional analysis was performed using Illumina® bead array technique Norwegian Microarray Consortium in Oslo, Norway (project no.: NMC-OSLO-0222).
Utilizing the Illumina® TotalPrep™-96 RNA Amplification Kit, biotin-labeled cRNA was synthesized from 500 ng total RNA by first-and second strand reverse transcription followed by in vitro transcription of cRNA. RNA quantity was determined using a NanoDrop Spectrophotometer while RNA size and integrity were determined using the Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and RNA integrity number (RIN) values. Values above 7 were considered acceptable. All samples had RIN values above 8. 750 ng of biotin-labeled cRNA were analyzed using a HumanHT-12 v4 Expression BeadChip. Data from the microarray were filtered and processed using the software program TIBCO Spotfire® (TIBCO Spotfire, Boston, MA, USA). Datasets from the arrays were grouped in Spotfire® and filtered for empty records and genes with signal intensities below the cut-off of 400 set equal to background intensity. Triplicates of datasets from stimulated and unstimulated cells were averaged and fold changes of gene regulation were calculated relative to unstimulated cells.
Western Blotting
HOK were seeded at the desired density (dependent on type of experiments) in 6-well plates and incubated overnight. overnight at 4 °C or for 2 h at room temperature. The blots were then washed three times in TBST for 10 min followed by incubation with alkaline phosphatase-conjugated donkey antigoat IgG (1:5000; Jackson ImmunoResearch Laboratories) for 1 h at room temperature. The blots were washed in TBST buffer before visualization with a solution containing BCIP/NBP (5-bromo-4-chloro-3'-indolyphosphate/ nitro-blue tetrazolium). Quantification of IL-36γ protein, phosphorylated ERK1, p-38 and JNK was carried out using the image processing program ImageJ ( Schneider, Rasband & Eliceiri, 2012 ).
ELISA
HOK were seeded at a density of approximately 60 000 cells cm -2 in 6-well plates and incubated overnight. The cells were then serum-starved for 24 h before stimulation with LPA (10 μM) in keratinocyte SFM medium (without BPE). The conditioned medium was collected after 6h or 24 h. IL-6, IL-8 and IL-36ɣ secretion were detected using a Human IL-6 mini TMB ELISA Development Kit (Peprotech, Rocky Hill, NJ, USA), Human IL-8 Mini TMB ELISA Development Kit (Peprotech) and Human IL-36G (IL-1F9) ELISA kit (ThermoFisher Scientific), respectively, according to the manufacturer's protocol. All reactions were performed in duplicate.
Statistical analysis
Statistical analysis was carried out with SigmaPlot 13 software (Systat Software, Inc., San Jose, CA, USA). Comparisons between different time points were performed with one way repeated measures analysis of variance (RM-ANOVA). When there were significant differences (p < 0.05), pairwise comparisons were carried out with paired t-tests, using the Holm-Sidak method for adjustment of multiple comparisons. The data were presented as mean ± standard deviation. For western blotting of IL-36ƴ protein, the paired t-test was used.
Results and discussion
3.1. LPA receptor expression and signal transduction in human oral keratinocytes.
Of the 6 known G protein-coupled receptors (LPA1-6) (Yanagida, Kurikawa, Shimizu & Ishii, 2013) , LPA1, LPA5 and LPA6 were predominantly transcribed in unstimulated HOK (Fig.   1 ). LPA3 was moderately and LPA2 and LPA4 were negligibly expressed. Skin keratinocytes express LPA1, LPA2 and LPA3 (Sauer et al., 2004) , while their expression of LPA4, LPA5 and LPA6 is unknown. Oral carcinoma cell lines express LPA1-6 at different levels (Brusevold et al., 2014) . This indicates that the LPA receptor profiles are unique for different cell types.
To determine that the LPA receptors were functionally active in HOK, we investigated the ability of LPA to activate intracellular signaling cascades. LPA induced phosphorylation of ERK1 at 5, 10 and 15 min ( Fig. 2 ; p < 0.05, RM-ANOVA and paired t-tests). Phosphorylation of ERK2 was induced at 5 min, but did not reach statistical significance. LPA activated phosphorylation of p38 MAPK at 15 min (p < 0.05, RM-ANOVA and paired t-tests) (Fig. 2) . Phosphorylation of JNK was induced after 5 min (p < 0.05, RM-ANOVA and paired t-tests) but rapidly decreased (Fig. 2) . The observed MAP kinase activation is in line with studies on other cell types such as OSCC (Hwang, Lee, Park & Chung, 2012; Brusevold et al., 2014) , ovarian cancer cells (Fang et al., 2004) and aortic smooth muscle cells (Hao, Tan, Wu, Xu and Cui, 2010) .
The gene expression profile of LPA-stimulated human oral keratinocytes
After establishing that LPA can induce signaling in HOK, we set out to analyze the cells' gene expression after LPA stimulation. LPA significantly regulated a wide range of genes, both at 2 and 6 h. We therefore rather focused on fold changes and chose the group of genes that showed the strongest up-regulation (more than 4-fold at either time point; Table 1 ) for further study. As outlined below, the majority (27/36) of those genes were found to encode for gene products that participate in the processes of chemotaxis, inflammation, remodeling of extracellular matrix, and cellular growth and motogenicity, all essential for wound healing.
Chemotaxis and cellular migration
Chemokines are essential in the early stages of wound healing (Singer & Clark 1999) .
Keratinocytes, leukocytes, myofibroblasts and endothelial cells need to be recruited to the wound site to start the healing process (Martin, 1997) . Leukocyte recruitment is started minutes and keratinocyte migration 3 -6 h after wounding (Martin, 1997) .
The transcripts for CXCL1, CXCL2, CXCL8, CCL20 and HB-EGF were strongly upregulated by LPA at 2 h, and all decreased at 6 h (Table 1 ). CCL5 increased from 2 to 6 h (Table 1) . ELISA showed that LPA induced secretion of CXCL8 (IL-8) after 6 h and 24 h (p < 0.05; RM-ANOVA, paired t-test) (Fig. 3) . This shows that LPA can regulate gene expression and secretion in HOK of chemokines that can attract neutrophils (CXCL1, -2 and -8), im-mature dendritic cells (DC), effector/ memory T-cells and B-cells (CCL20) and macrophages (CCL5) (Steude, Kulke & Christophers, 2002; Weathington et al., 2006; Schutyser, Struyf & Damme, 2003; Spiekstra et al., 2007) . CXCL1, -2 and -8 also increase cellular migration of keratinocytes (Steude et al., 2002; Kroeze et al., 2012) . In vivo, LPA promotes macrophage recruitment and accelerates wound closing in rat skin (Balazs et al., 2000) . Heparin-binding EGF-like growth factor (HB-EGF) is another major factor promoting migration of skin keratinocytes and fibroblasts (Seeger & Paller, 2015) . Prolonged exposure to high local chemokine concentrations can be detrimental and this matches our finding that the mediators were downregulated after 6 h. This is in line with in vivo data derived from a wound healing model in rats (Demoyer et al., 2000) .
In addition to being chemokines, CXCL1, CXCL2 and CCL20 display antimicrobial activity (Yang et al., 2003) . Their early and strong expression may therefore be a factor to secure a disrupted epithelial barrier from microbial invasion in the early phases of wound healing, before other antimicrobial systems are established (Pastar et al., 2014) . Genes coding for other antimicrobial peptides, such as S100A8 and S100A9, were also upregulated by LPA at 6 h, but their gene expression did not reach four fold.
Inflammation
The inflammatory response is an early phase in wound healing and a delicate balance between pro-and anti-inflammatory mediators is crucial in re-achieving tissue homeostasis following injury (Eming, Krieg & Davidson, 2007) .
The expression of several pro-inflammatory genes showed strong upregulation, including IL1F9, IL6, TNF, CSF2 and SGPP2, encoding IL-36γ, IL-6, TNF-α, GM-CSF and SPP-2, respectively. ELISA showed that LPA induced the secretion of IL-6 after 6 h and 24 h (p < 0.05; RM-ANOVA, paired t-tests) (Fig. 3) . IL-36y was the third most up-regulated gene at 2 h (Table   1 ). We could not detect secretion of IL-36y as measured by ELISA of culture supernatant (data not shown), but Western blotting showed that this gene was translated at 24 h (p < 0.05; paired t-test) (Fig. 4) . This can be due to restricted or delayed secretion of IL-36γ (> 24 h) as the ELISA assay applied should have sufficient sensitivity to detect low IL-36y levels.
IL-36γ has previously not been shown to be regulated by LPA in any cell type. It increases the expression of CXCL1, CXCL8, CCL3, CCL5, and CCL20 in skin keratinocytes (Foster et al., 2014) , and IL-36y might therefore in part be responsible for the observed upregu-lation of CXCL1, CXCL8, CCL5 and CCL20. IL-6 and TNF-α promote wound healing by indirectly stimulating inflammation. IL-6 attracts neutrophils (Gallucci, Sloan, Heck, Murray, & O'Dell, 2004) and has a proliferative effect on keratinocytes (Barrientos, Stojadinovic, Golinko, Brem & Tomic-Canic, 2008 ). IL-6 and TNF-α can have both beneficial and detrimental effects, especially in chronic inflammation (Gabay, 2006; Barrientos et al. 2008) . The fact that both cytokines were upregulated at 2 h and were decreased at 6 h indicates a response toward tissue homeostasis. GM-CSF increases bone marrow production of myeloid cells and activates tissue resident macrophages and neutrophils (Wicks and Roberts, 2016) . SPP-2 plays a role in pro-inflammatory signaling in endothelial cells (Mechtcheriakova et al., 2007) . SPP2 has not earlier been reported to be expressed by HOK, nor regulated by LPA.
On the other hand, several inhibitors of inflammation were also upregulated by LPA, including TNFAIP3, TNIP1, IL1RN, IL1R2, IL13RA2, DUSP1, DUSP10 and NFKBIA (Table 1 ). The gene product of TNFAIP3 inhibits NF-κB activation as well as TNF-mediated apoptosis (Filkor et al., 2013) . TNIP1 encodes TNFAIP3 interacting protein 1, which also inhibits NF-κB activation by TNF and several other stimuli (Verstrepen, Carpentier, Verhelst & Beyaert, 2009 ). The gene product of IL1RN is a natural inhibitor of the pro-inflammatory effects of IL-1α and IL-1β and modulates a variety of IL-1-related immune and inflammatory responses.
IL1R2 acts as a decoy receptor for IL-1α and IL-1β (Garlanda, Riva, Bonavita & Mantovani, 2013) . IL13RA2 acts as a decoy receptor for IL-13 (Zhang et al., 1997) . DUSP1 is a negative regulator for the production of inflammatory cytokines (Huang & Tan, 2012) . DUPS10 modulates gene expression in innate immune cells, and is a negative regulator of inflammatory responses via inactivation of JNK (Patterson, Brummer, O'Brien & Daly, 2009) .
NFKBIA is also a gene encoding a negative regulator of NF-κB.
Taken together, the present findings indicate that LPA can contribute to establishment of early inflammation in the oral cavity by increasing transcription of genes encoding potent pro-inflammatory factors in HOK. This was, however, succeeded by a wave of inhibition consisting of downregulation of pro-inflammatory and upregulation of anti-inflammatory factors, which corresponds to well-regulated inflammation needed for successful wound healing. This notion is supported by in vivo studies in rats where LPA reduces mucosal damage and inflammation, and ameliorates intestinal epithelial injury (Sturm et al., 1999) .
Remodeling of extracellular matrix
The fibrin barrier at the wound site must be dissolved (Steffensen, Häkkinen & Larjava, 2001) . The main enzyme for fibrinolysis is plasmin derived from plasminogen in the blood clot. This activation is facilitated by matrix metalloproteases (MMPs) (Pastar et al., 2014) . MMPs also participate in remodeling of extracellular matrix (ECM) components (Visse & Nagase, 2003) . LPA upregulated expression of important genes involved in plasminogen activation, PLAUR and SERPINB2 (Table 1) , coding for urokinase-type plasminogen activator receptor (uPAR) and plasminogen activator inhibitor 2 (PAI-2), respectively. The gene expression of PLAU (coding for urokinase-type plasminogen activator, uPA) was also upregulated by LPA, although it did not reach a 4 fold increase. Genes coding for MMP-9 and MMP-10 were also strongly upregulated at 2 and 6 h. ADAMTS1, an ADAM metallopeptidase, was upregulated at 2 h but decreased at 6 h (Table 1) . uPAR binds the protease uPA which cleaves plasminogen, generating plasmin.
Plasmin cleaves and activates MMPs. Both plasmin and MMPs degrade many ECM components and fibrin, and activate growth factors. uPA and plasmin are antagonized by the serpins plasminogen activator inhibitor 1 (PAI-1; SERPINE1) and PAI2 (SERPINB2) (Smith & Marshall 2010) . To avoid excessive proteolysis and tissue damage, a precisely coordinated regulation of this system is required (Li, Chong, Huang & Tuan, 2003) . The finding that LPA regulates PLAU, PLAUR and SERPINB2 matches the upregulation seen in keratinocytes under conditions of re-epithelialization, both in organotypic keratinocyte co-cultures and epidermal lesions in vivo (Bechtel et al., 1998) . MMPs are important in the resorption of extracellular matrix components in physiological and pathological processes (Visse & Nagase 2003) . In early wounds, migrating wound keratinocytes express MMP1, MMP9 and MMP10.
After re-epithelialization is complete, MMP9 expression is sustained, whereas the expression of the other MMPs is downregulated (Parks, 1999; Steffensen, Häkkinen & Larjava, 2001) .
ADAMTS is a protease with diverse roles in cell surface remodeling and regulation of growth factor availability, and in mediating cell-cell-matrix interaction (Roy, Zhang & Moses, 2006) . Taken together, LPA strongly induces genes in HOK that are involved in degradation and remodeling of the fibrin clot and extracellular matrix, essential for wound healing.
Cellular growth
Cell proliferation is fundamental for wound healing. LPA significantly (p < 0.05) upregulated expression of genes coding for the growth factors EDN1 and CSF2 (2 and 6 h).
Endothelin-1 protein, the gene product of EDN1, is an autocrine growth factor for human keratinocytes, while suppressing cell differentiation (Tsuboi et al., 1994) . GM-CSF (encoded by CSF2) takes part in the inflammatory process as outlined above but is also secreted by keratinocytes shortly after skin wounding (Mann, Breuhahn, Schirmacher, & Blessing, 2001) and its injection into human skin induces keratinocyte proliferation (Braunstein et al., 1994) .
On the other hand, cell proliferation restricting factors such as DKK1 and EFNA1 were upregulated at 2 h but downregulated at 6 h (Table 1 ). DKK1 encodes dickkopf 1 (Dkk1), an inhibitor of Wnt/β-catenin pathway (Niehrs, 2006) , inhibits epithelial cell proliferation and differentiation (Koch et al., 2011) . EFNA1, encoding ephrin-A1, induces cornification while suppressing wound healing-associated genes, and inhibits keratinocyte proliferation (Walsh & Blumenberg, 2011) . This can point to a prioritization of the HOK's response in the early phase of wound healing where they preferentially migrate and not proliferate or differentiate, to close the wound edge (Singer & Clark, 1999) , a process termed restitution. In vivo study in skin keratinocytes supports our finding (Sturm et al., 1999) .
Conclusions
HOK express functional LPA receptors which activate the MAPK intracellular signaling pathways and LPA exposure strongly induced transcription of a range of mediators in the cells. We also detected translation and secretion of selected cytokines. Genes involved in chemotaxis and early inflammation were transiently upregulated and subsequently downregulated in HOK exposed to LPA. Early and intermediate up-regulation of genes involved in remodeling of extracellular matrix and cellular growth was also seen. These observations indicate that LPA, present in saliva and released from activated platelets at an oral wound site, can activate oral keratinocytes to produce essential factors involved in the early phases of wound healing. This means that administration of LPA could be a valuable approach to promote oral wound healing, especially in patients with reduced wound healing capacity, e.g. persons receiving radiotherapy, uncontrolled diabetic patients, and patients receiving high doses of bisphosphonates. 
